Amarin reported $361.57M in Current Liabilities for its second fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Current Liabilities Change
DBV Technologies DBVT:US 30.43M 4.4M
Aerie Pharmaceuticals AERI:US $ 119.66M 4.37M
Alnylam Pharmaceuticals ALNY:US $ 657.68M 51.72M
Amarin AMRN:US $ 361.57M 61M
AstraZeneca AZN:LN 1791796.84M 60282.28M
Epizyme EPZM:US $ 34.95M 4.01M
Esperion Therapeutics ESPR:US $ 82.28M 3.19M
GlaxoSmithKline GSK:LN 3783500M 1355700M
Halozyme Therapeutics HALO:US $ 199.51M 87.82M
Heron Therapeutics HRTX:US $ 109.5M 16.5M
Intercept Pharmaceuticals ICPT:US $ 151.43M 0.39M
IONIS PHARMACEUT IONS:US $ 267.81M 39.36M
JAZZ PHA JAZZ:US $ 705.44M 31.97M
Nektar Therapeutics NKTR:US $ 104.98M 0.3M
Neurocrine Biosciences NBIX:US $ 285.7M 32.2M
Novartis NOVN:VX SF 27646M 2161M
Teva Pharmaceutical Industries TEVA:US $ 10996M 617M